Novavax, along with manufacturing partner the Serum Institute of India, has applied for an emergency use listing (EUL) for its investigational COVID-19 vaccine with the World Health Organization (WHO).

An EUL would enable NVX-CoV2373, a nanoparticle protein-based vaccine, to be shipped to numerous developing nations under the WHO-backed COVAX vaccine-sharing program.

NVX-CoV2373 is currently being evaluated in two late-stage trials. One in the UK, where the vaccine has shown 89.7 percent efficacy, and one in the U.S. Mexico where the shot demonstrated a 90.4 percent efficacy, according to the Gaithersburg, Md.-based drugmaker.

Novavax said it plans to file for FDA Emergency Use Authorization of NVX-CoV2373 in the current quarter.